Metabolic dysfunction-associated steatotic liver disease in internal medicine: bridging fibrosis risk stratification, new drug therapy, and practical management

Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in adults with type 2 diabetes or obesity, and fibrosis stage, rather than steatosis, is a key prognostic determinant. We review fibrosis risk stratification in these adults, the randomized evidence for newly approved and repurposed drugs, and a stepwise plan combining both, with attention to Saudi Arabia. We searched PubMed in November 2026 and cite forty-six sources. A global meta-analysis places the disease in about two thirds of people with type 2 diabetes. American guidance recommends the Fibrosis-4 index (FIB-4) first; one analysis of two primary care cohorts found that it under-triages people with diabetes or obesity, but evidence conflicts, and we keep FIB-4 first and regard going directly to elastography as an unproven alternative (authors' expert opinion). Resmetirom and semaglutide improved histology in phase 3 trials and received accelerated United States approval for steatohepatitis with moderate to advanced fibrosis without cirrhosis, semaglutide on a planned interim analysis; tirzepatide improved histology in a phase 2 trial; and one open-label randomized trial found more resolution of steatohepatitis after bariatric surgery than with lifestyle modification. Pioglitazone, vitamin E and sodium-glucose cotransporter 2 inhibitors have narrower evidence. A 2026 Saudi consensus, whose literature review ended in May 2024, states that resmetirom was not yet approved there. We propose a stepwise approach (authors' expert opinion): assess fibrosis risk with FIB-4 and elastography, treat weight and cardiometabolic risk in everyone, consider drug therapy for stage 2 or 3 fibrosis, and refer early when risk is high. Abbreviations: AASLD, American Association for the Study of Liver Diseases; ADA, American Diabetes Association; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4 index; MASH, metabolic dysfunction-associated steatohepatitis; MetALD, metabolic dysfunction with more alcohol intake than MASLD allows; NASH, non-alcoholic steatohepatitis; SGLT-2, sodium-glucose cotransporter 2; VCTE, vibration-controlled transient elastography.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-22
DOI
https://doi.org/10.5281/zenodo.24430858
Primary Topic
Liver Disease Diagnosis and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Metabolic dysfunction-associated steatotic liver disease in internal medicine: bridging fibrosis risk stratification, new drug therapy, and practical management

Majed Alqahtani, Salman Mashary Alharbi
Zenodo (CERN European Organization for Nuclear Research)
Liver Disease Diagnosis and Treatment
preprint

Metabolic dysfunction-associated steatotic liver disease in internal medicine: bridging fibrosis risk stratification, new drug therapy, and practical management

Majed Alqahtani, Salman Mashary Alharbi
preprint en

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in adults with type 2 diabetes or obesity, and fibrosis stage, rather than steatosis, is a key prognostic determinant. We review fibrosis risk stratification in these adults, the randomized evidence for newly approved and repurposed drugs, and a stepwise plan combining both, with attention to Saudi Arabia. We searched PubMed in November 2026 and cite forty-six sources. A global meta-analysis places the disease in about two thirds of people with type 2 diabetes. American guidance recommends the Fibrosis-4 index (FIB-4) first; one analysis of two primary care cohorts found that it under-triages people with diabetes or obesity, but evidence conflicts, and we keep FIB-4 first and regard going directly to elastography as an unproven alternative (authors' expert opinion). Resmetirom and semaglutide improved histology in phase 3 trials and received accelerated United States approval for steatohepatitis with moderate to advanced fibrosis without cirrhosis, semaglutide on a planned interim analysis; tirzepatide improved histology in a phase 2 trial; and one open-label randomized trial found more resolution of steatohepatitis after bariatric surgery than with lifestyle modification. Pioglitazone, vitamin E and sodium-glucose cotransporter 2 inhibitors have narrower evidence. A 2026 Saudi consensus, whose literature review ended in May 2024, states that resmetirom was not yet approved there. We propose a stepwise approach (authors' expert opinion): assess fibrosis risk with FIB-4 and elastography, treat weight and cardiometabolic risk in everyone, consider drug therapy for stage 2 or 3 fibrosis, and refer early when risk is high. Abbreviations: AASLD, American Association for the Study of Liver Diseases; ADA, American Diabetes Association; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4 index; MASH, metabolic dysfunction-associated steatohepatitis; MetALD, metabolic dysfunction with more alcohol intake than MASLD allows; NASH, non-alcoholic steatohepatitis; SGLT-2, sodium-glucose cotransporter 2; VCTE, vibration-controlled transient elastography.

Zenodo (CERN European Organization for Nuclear Research)
King Saud University (SA)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon